678-366-7933
Product Library
Emergency Department Management of Postthrombolysis Intracranial Hemorrhage
What ED Clinicians Need to Know
Symptomatic intracranial hemorrhage is the most dreaded complication of intravenous thrombolysis for acute ischemic stroke, occurring in 2% to 7% of treated patients. This issue provides a structured, time-sensitive approach to recognizing postthrombolysis intracranial hemorrhage, distinguishing it from other causes of neurological deterioration, and confirming the diagnosis with appropriate imaging, including the role of dual-energy CT in differentiating true hemorrhage from contrast staining.
The issue also reviews key management steps, including stopping the thrombolytic infusion at the first sign of deterioration, correcting coagulopathy with cryoprecipitate and antifibrinolytic agents, individualized blood pressure control, the limited role of platelet transfusion, indications for neurosurgical intervention, and escalation to neurocritical care. Eligibility criteria and contraindications for thrombolysis, along with risk factors for hemorrhage, are covered to support prevention as well as treatment.
Why This Topic Matters in the ED
- Postthrombolysis intracranial hemorrhage most commonly occurs within 12 hours of administration, when many patients are still in the ED; emergency clinicians may be the first to notice neurological decline.
- This responsibility applies in all settings, from tertiary centers with in-house stroke coverage to rural and remote EDs relying on telestroke support, where stabilization and transfer decisions fall to the emergency clinician.
- The differential for neurological deterioration after thrombolysis is broad, and a structured approach prevents missed or delayed diagnosis.
- Reversal is time-sensitive and evidence is limited, so familiarity with guideline-recommended agents, institutional protocols, and a bundled order-set approach prevents confusion and delay when minutes matter.
- Blood pressure management is nuanced, balancing the risk for hematoma expansion against the risk for compromising brain perfusion.
Clinical Content at a Glance
Clinical Q&A
- What are the eligibility criteria and contraindications for intravenous thrombolysis?
- Eligibility hinges on an accurately verified “last known well,” with treatment windows established by major trials and, in select patients, extended through advanced imaging. Absolute and relative contraindications focus on mitigating hemorrhage risk.
- How is postthrombolysis intracranial hemorrhage recognized and confirmed?
- Any neurological deterioration after thrombolytic administration warrants stopping the infusion and obtaining STAT noncontrast CT of the head — without waiting for imaging confirmation to act. The differential for deterioration extends well beyond hemorrhage, and in postthrombectomy patients, dual-energy CT can help distinguish true hemorrhage from contrast staining.
- What reversal agents are recommended?
- Cryoprecipitate and the antifibrinolytic agents tranexamic acid and aminocaproic acid are the mainstays, with platelet transfusion reserved for limited circumstances. The evidence base is limited, and guidance has evolved between the 2017 and 2026 AHA/ASA guidelines.
- How should blood pressure be managed?
- There are no dedicated, evidence-based blood pressure targets specific to postthrombolysis intracranial hemorrhage. Management is individualized through multidisciplinary consultation, balancing the risk for hematoma expansion against the risk for compromising brain perfusion.
- When is escalation of care needed?
- Declining mentation, brainstem signs, and large or expanding hemorrhages may warrant intubation, neurosurgical consultation, or transfer. Even small, petechial hemorrhages call for close neuromonitoring, as patients remain at risk for worsening for up to 24 hours.
Case Snapshots
CASE 1 — Deterioration After Tenecteplase: A 75-year-old woman’s NIHSS score jumps from 4 to 10 forty-five minutes after tenecteplase, with rising blood pressure and new parenchymal and subarachnoid hemorrhages on CT. The issue walks through reversal and blood pressure management in this time-critical scenario.
CASE 2 —Postthrombolysis Pontine Hemorrhage: A 62-year-old woman receives alteplase based on an EMS-reported last known well of 45 minutes. The issue explores the risk factors for hemorrhage and why verified last known well remains the most critical eligibility criterion.
CASE 3 — Hyperdensity on Postprocedural CT: A 65-year-old man has a new right frontal hyperdensity on CT after tenecteplase and mechanical thrombectomy, with no neurological deterioration. The issue considers how to distinguish contrast staining from true hemorrhage and whether reversal is warranted.
Clinical Tools
- Reference table of selected absolute and relative contraindications to intravenous thrombolysis
- Differential diagnosis table for continued neurological deterioration following intravenous thrombolysis
- Radiographic classification of postthrombolysis intracranial hemorrhage on CT, with imaging examples
- Sample emergency department order set for postthrombolysis intracranial hemorrhage
- Figures comparing the mechanisms of tenecteplase and alteplase and standard versus dual-energy CT
- Clinical pathway for detection and management of postthrombolysis intracranial hemorrhage in the ED
- Links to online NIHSS and modified Rankin Scale calculators at MDCalc.com
Risk Management Pitfalls
- Failing to provide close monitoring in the first hours after thrombolytic administration
- Continuing the thrombolytic infusion despite subtle neurological worsening instead of stopping it and obtaining STAT CT
- Giving thrombolytics when the last known well cannot be verified with certainty
- Transfusing platelets without a clear indication
- Mistaking contrast staining for hemorrhage on postthrombectomy CT and triggering unnecessary reversal or surgical consultation
Key References
Following are the most informative references cited in this paper, as determined by the author.
3. * Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2026;57. (Clinical practice guidelines) DOI: https://doi.org/10.1161/STR.0000000000000513
9. * Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48(12):e343-e361. (Clinical practice guidelines) DOI: https://doi.org/10.1161/STR.0000000000000152
10. * Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the Neurocritical Care Society and the Society of Critical Care Medicine. Crit Care Med. 2016;44(12):2251-2257. (Clinical practice guidelines) DOI: https://doi.org/10.1007/s12028-015-0222-x
11. * Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282-e361. (Clinical practice guidelines) DOI: https://doi.org/10.1161/STR.0000000000000407
CME Information
- 4 CME credits (available for subscribers)
- Includes Stroke and Pharmacology
- View complete CME Information here
